WVE: Durable RNA editing and Inhibin E programs advance, with pivotal data and regulatory updates expected
RNA editing programs have shown high specificity and durable correction in clinical studies, with AATD and PNPLA3 advancing toward pivotal trials and regulatory discussions. The Inhibin E program is progressing in obesity and cardiometabolic indications, with combination and maintenance studies pla…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.